SCHEMBL4688655

SCHEMBL4688655

COCCCN1C(=O)C(Cl)=C(c2ccccc2)C1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
MAPT P10636 4/20 0.43
ALDH1A1 P00352 3/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42
LCK P06239 1/20 0.41
RAD51 Q06609 1/20 0.40
RECQL P46063 1/20 0.39
NR1H2 P55055 4/20 0.39
NR1H3 Q13133 4/20 0.39
POLB P06746 1/20 0.39
PTPN1 P18031 1/20 0.39
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4685696 0.91 ALDH1A1 (0.43) MAPTALDH1A1RAB9ASMN1; SMN2LMNA
SCHEMBL5748763 0.84 NR1H2 (0.65) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL4685924 0.84 NPC1 (0.46) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL4685918 0.77 NR1H2 (0.60) MAPTALDH1A1LMNALCKRAD51
SCHEMBL4692961 0.77 RAD51 (0.41) KMT2AMAPTALDH1A1RAB9ASMN1; SMN2
SCHEMBL5790936 0.76 NR1H2 (0.67) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL10719302 0.75 RAB9A (0.67) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL4689452 0.75 NR1H2 (0.72) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL5746128 0.74 NR1H2 (0.51) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL29644739 0.72 LCK (0.57) MEN1KMT2ALMNATSHRLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432288-B2 Pyrrole-2,5-dione derivatives as Liver X receptor modulators ASTRAZENECA AB (SE) 2008-10-07 US disclosed
EP-1646626-B1 PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2008-07-02 EP disclosed
US-20060235015-A1 Pyrrole-2,5-dione derivatives as liver x receptor modulators ASTRAZENECA AB (SE) 2006-10-19 US disclosed
EP-1646626-A1 PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS AstraZeneca AB (SE) 2006-04-19 EP disclosed
WO-2005005417-A1 PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235015-A1 Pyrrole-2,5-dione derivatives as liver x receptor modulators NR1H2, NR1H3, SREBF2 MEN1 4511/4885KMT2A 3674/4885MAPT 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.